Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18206800 | 1.00 | CA1 (0.49) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL29400712 | 0.94 | TDP1 (0.48) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL9931542 | 0.94 | TDP1 (0.48) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL3754005 | 0.94 | TDP1 (0.48) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL12604209 | 0.91 | MEN1 (0.48) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL30895563 | 0.91 | MEN1 (0.48) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL21901505 | 0.90 | MEN1 (0.44) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL16076756 | 0.89 | MEN1 (0.49) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL12509746 | 0.89 | SIRT1 (0.38) | CA1CA2TDP1ATMNPSR1 | |
| SCHEMBL15893373 | 0.87 | TDP1 (0.44) | CA1CA2TDP1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | ALBANY MOLECULAR RESEARCH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | 3ST RESEARCH LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| WO-2016207090-A2 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226456-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | CA1 3246/4885CA2 2575/4885TDP1 675/4885 |
| US-10695342-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
| US-11020386-B2 | Methods and compositions for preventing opioid abuse | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
| US-20190262463-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | CA1 3246/4885CA2 2575/4885TDP1 675/4885 |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
| US-10973923-B2 | Site specific homogeneous with KSP inhibitors | KIF5B, KIF15, KIF2C | CA1 3246/4885CA2 2575/4885TDP1 675/4885 |
| US-20210252161-A1 | SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS | KIF5B, KIF15, KIF2C | CA1 3246/4885CA2 2575/4885TDP1 675/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | CA1 1800/4885CA2 3127/4885TDP1 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.